Eimer M, Carter B L
Drug Intell Clin Pharm. 1987 Apr;21(4):340-2. doi: 10.1177/106002808702100408.
A case of carbamazepine neurotoxicity following the addition of diltiazem is reported. A patient with previously stable carbamazepine serum concentrations was treated with diltiazem for atrial fibrillation and a rapid ventricular response. After three days on the combined regimen, the patient developed neurological symptoms resulting in hospitalization. After a review of the patient's medication usage and carbamazepine concentrations, an interaction between diltiazem and carbamazepine was suspected. Carbamazepine's elimination appears to have been decreased, resulting in neurotoxicity. The toxicity resolved when the carbamazepine dosage was decreased 62 percent.
报告了1例加用维拉帕米后出现卡马西平神经毒性的病例。1例先前卡马西平血清浓度稳定的患者因心房颤动和快速心室反应接受维拉帕米治疗。联合用药3天后，患者出现神经症状并住院。在复查患者的用药情况和卡马西平浓度后，怀疑维拉帕米与卡马西平之间存在相互作用。卡马西平的清除似乎减少，导致神经毒性。当卡马西平剂量减少62%时，毒性消失。
